Rosenbaum Jay D. trimmed its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 9,416 shares of the medical research company’s stock after selling 210 shares during the period. Amgen accounts for approximately 3.3% of Rosenbaum Jay D.’s investment portfolio, making the stock its 6th biggest holding. Rosenbaum Jay D.’s holdings in Amgen were worth $1,735,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after acquiring an additional 482,760 shares in the last quarter. Norges Bank bought a new position in shares of Amgen in the 4th quarter valued at approximately $1,283,248,000. Nordea Investment Management AB raised its stake in shares of Amgen by 5.0% in the 1st quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after acquiring an additional 225,485 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Amgen by 5.7% in the 4th quarter. Legal & General Group Plc now owns 3,241,580 shares of the medical research company’s stock valued at $631,039,000 after acquiring an additional 174,360 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Amgen by 18.0% in the 4th quarter. Two Sigma Advisers LP now owns 2,069,296 shares of the medical research company’s stock valued at $402,830,000 after acquiring an additional 315,600 shares in the last quarter. Institutional investors and hedge funds own 78.96% of the company’s stock.
AMGN has been the topic of a number of recent analyst reports. Citigroup reissued a “buy” rating on shares of Amgen in a research note on Monday. Royal Bank of Canada reaffirmed a “hold” rating on shares of Amgen in a research report on Sunday. Morgan Stanley dropped their price target on Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. Wells Fargo & Co lifted their price target on Amgen from $197.00 to $202.00 and gave the stock a “market perform” rating in a research report on Monday. Finally, BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Amgen has an average rating of “Buy” and an average price target of $211.44.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. Amgen’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $3.83 earnings per share. As a group, analysts predict that Amgen, Inc. will post 14.25 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio is presently 40.28%.
In other news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now owns 16,336 shares in the company, valued at $2,990,141.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,425 shares of company stock worth $804,312. 0.25% of the stock is currently owned by company insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Market Capitalization and Individual Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.